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Since the late 1960´s, a great interest in the use of bioceramic materials for biomedical applications has been developed. 
In a previous paper, the authors reviewed crystalline bioceramic materials “sensus stricto”, it is to say, those ceramic 
materials, constituted for non-metallic inorganic compounds, crystallines and consolidates by thermal treatment of 
powders at high temperature. In the present review, the authors deal with those called bioactive glasses and glass-
ceramics. Although all of them are also obtained by thermal treatment at high temperature, the first are amorphous and 
the second are obtained by devitrification of a glass, although the vitreous phase normally prevails on the crystalline 
phases. 
After an introduction to the concept of bioactive materials, a short historical review of the bioactive glasses development 
is made. Its preparation, reactivity in physiological media, mechanism of bonding to living tissues and mechanical 
strength of the bone-implant interface is also reported. Next, the concept of glass-ceramic and the way of its preparation 
are exposed. The composition, physicochemical properties and biological behaviour of the principal types of bioactive 
glasses and glass-ceramic materials: Bioglass®, Ceravital®, Cerabone®, Ilmaplant® and Bioverit® are also reviewed. Finally, 
a short review on the bioactive-glass coatings and bioactive-composites and most common uses of bioactive-glasses and 
glass-ceramics are carried out too. 
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Vidrios y Vitrocerámicos Bioactivos
Desde finales de los años sesenta, se ha despertado un gran interés por el uso de los materiales biocerámicos para 
aplicaciones biomédicas.
En un trabajo previo, los autores hicieron una revisión de los denominados materiales biocerámicos cristalinos en sentido 
estricto, es decir, de aquellos materiales, constituidos por compuestos inorgánicos no metálicos, cristalinos y consolidados 
mediante tratamientos térmicos a altas temperaturas. En el presente trabajo, los autores revisan el desarrollo de los 
vidrios bioactivos (biovidrios) y de las vitrocerámicas bioactivas. Si bien todos ellos son obtenidos también por tratamiento 
térmico a altas temperaturas, los primeros son amorfos y los segundos son obtenidos por desvitrificación de un vidrio, si 
bien la fase vítrea normalmente predomina sobre las fases cristalinas.
Después de una introducción al concepto de material bioactivo, se expone una breve revisión histórica del desarrollo 
de los vidrios bioactivos. A continuación se describe su obtención, reactividad en suero fisiológico artificial, mecanismo 
de unión al tejido vivo y resistencia mecánica de la interfaz hueso-implante. Posteriormente, se expone el concepto 
de material vitrocerámico y el proceso de su obtención así como también se describen los principales tipos de vidrios 
y vitrocerámicos bioactivos (Bioglass®, Ceravital®, Cerabone®, Ilmaplant® and Bioverit®), sus composiciones, sus 
propiedades físico-químicas y sus comportamientos biológicos. Finalmente, se lleva a cabo también una corta revisión 
de los recubrimientos con vidrios bioactivos y de los materiales compuestos (composites) bioactivos así como de los usos 
más comunes de los vidrios y vitrocerámicos bioactivos.
Palabras clave:  Vidrios bioactivos, Biovidrios, Vitrocerámicos bioactivos, Recubrimientos bioactivos, Composites bioactivos.
1. INTRODUCTION
The concept of bioactive material is midway between 
those of inert material and resorbable material. Although 
a number of definitions of bioactivity have been reported, 
one by Hench (1, 2) is especially simple: the property of an 
implanted material that allows it to bond to living tissue.
As stated in dealing with crystalline bioceramic materials 
in a previous paper (3), bioactive materials, which include 
ceramics, glasses and glass-ceramics, can attach directly to 
bone tissue via a biologically active carbohydroxyapatite 
(CHA) layer, which provides the interfacial bonding. Such a 
layer is chemically and structurally equivalent to the mineral 
phase of bone.
Bioactive glasses and glass-ceramics have been 
developed in response to the need to suppress interfacial 
mobility in implanted bioinert ceramics. Thus, in 1967, 
Hench proposed, to the US Army Medical Research and 
Development Command, to conduct research with a view 
to change the chemical composition of glasses, in order to 
enable their interaction with the physiological system and 
provide chemical bonding between living tissue and the 
implant surface. This away, in 1971, Hench et al. (4) showed, 
for the first time, that a material made by the man could 
bond to bone. The invention, named Bioglass®, was the first 
bioactive glass material ever developed.
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From Bioglass® 45S5, Hench et al. developed and 
characterized a large series of glasses based on the SiO2-
CaO-Na2O-P2O5 quaternary system, all containing 6 wt% 
P2O5. Table I shows the compositions of some of them. All 
were characterized in terms of a bioactivity index, which was 
defined as the time needed for 50% of an implant surface to 
attach to bone (t0.5) (1), i.e.
IB = [100/t0.5] (days
-1)
According to Hench and Wilson (5), bioactive materials 
include hydroxyapatite (HA) ceramics, glasses, glass-
ceramics and surface-active composite materials. Since 
hydroxyapatite ceramics were dealt with in a previous paper 
about crystalline bioceramic materials (3); in this work will 
only be made reference to the bioactive glasses and glass-
ceramics.
2. BIOACTIVE GLASSES
The finding by Hench et al. (4) in the early 1970s that 
some SiO2-CaO-Na2O-P2O5 glasses induce the formation 
of no fibrous tissue on contact with living tissue, but 
rather bond chemically to it, arouse much interest in the 
development of bioactive glasses and glass-ceramics, and 
their use as biomedical materials.
The primary requirements to be met by a bioactive 
glass is that it should contain no extraneous or hazardous 
elements for the living body but contain calcium and 
phosphorus, which are the major constituents of the mineral 
phase in bone tissue. As stable vitreous network builder 
silica was selected, what allow to develop phosphate glasses 
with a silica-rich matrix.
The first bioactive glass (Bioglass®), which was developed 
by Hench et al. (6) and named Bioglass® 45S5, exhibits a high 
bioactivity and can join readily even to soft tissues. This is 
the most widely studied bioactive glass, which consists of 45 
wt% SiO2, 24.4 wt% CaO, 24.5 wt% Na2O and 6 wt% P2O5.
Bioglass® 45S5 was based on the SiO2-CaO-Na2O-P2O5 
system. As can be seen in Figure 1, the projection of its 
composition on the SiO2-CaO-Na2O system falls near a 
eutectic point, but far from the typical compositions of soda-
lime glasses, which contain much more silica.
The composition of Bioglass® 45S5 in three different 
microstructural forms (viz. amorphous, partially crystalline 
and fully crystalline) was studied both in vitro and in vivo. 
All implants examined bonded to a rat femur model within 
6 weeks, with no differences in this respect between the 
vitreous and crystalline implants (4, 8, 9).
Fig. 1- SiO2-CaO-Na2O system (7) showing the position of tradi-
tional sodalime- glasses and the projection of the composition of the 
Bioglass® 45S5.
Fig. 2- Section corresponding to 6 wt% P2O5 in the system SiO2-CaO-
Na2O-P2O5 and isobiactivity lines as a function of the wt% composi-
tion (10). (*Bioglass® 45S5, qCeravital®, lBioglass®).
TABlE I. COMPOSITIONS IN WT% OF SOME glASSES.
Bioglass SiO2 CaO Na2O P2O5 B2O3 F2Ca K2O
45S5 45 24.5 24.5 6.0
45S5F 43 12 23 6.0 16
45B15S5 30 24.5 24.5 6.0 15
45B5S5 40 24.5 24.5 6.0 5
KCP1 45 24.5 6.0 24.5
45S5-N 50 24.5 19.5 6.0
45S5-C 50 19.5 24.5 6.0
This allowed to establish a series of isobioactivity lines 
as a function of the glass composition that are shown in the 
6 wt% P2O5 section of the SiO2-CaO-Na2O-P2O5 system (Fig. 
2). All glasses lying in region A, in the centre of the figure, 
were bioactive and bonded to bone. All them containing 
less than 60 mol% of SiO2 and diminishing their bioactivity 
dramatically with a slight increase of this silica proportion. 
Region A includes a central composition zone of IB > 8, 
bound by a dotted line in Fig. 2, where the glasses bond to 
both bone and soft tissues. On the other hand, the glasses in 
region B behaved as inert materials and were encapsulated 
by fibrous tissue upon implantation. The glasses in region C 
were reabsorbed within a few days of implantation. Finally, 
in the region D glasses cannot be obtained.
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alkalis, with less than 5 wt% of such oxides (22)
From the foregoing it follows that a wide range of 
bioactive vitreous compositions exists, which can be used, in 
theory, to adapt their reactivity to various clinical uses. Such 
a high flexibility is an outstanding feature that sets them 
apart from other biomaterials.
2.1. Preparation of bioactive glasses
Bioactive glasses are typically prepared from high-purity 
raw materials as their quality strongly influences that of the 
end-product. Such materials include highly pure quartz or 
silica sand, sodium and/or potassium carbonates of reactive 
grade, calcium phosphates containing no constitution water, 
less often, high-purity wollastonite (CaSiO3), etc. Accurately 
weighed amounts of the ingredients are melted (usually 
in Pt or Pt/Rh crucibles), the melt being homogenized 
as required and care being exercised to avoid the loss of 
especially volatile components such as Na2O and P2O5. The 
sol-gel process is frequently used starting from appropriate 
organic or inorganic soluble salts as raw materials (23) 
The melting temperature can range from 1200 to 1450 ºC, 
depending on the particular composition. The melt is cast in 
graphite moulds, which do not contaminate or adhere to the 
glass, or in steel moulds. Annealing of the glass is essential 
with a view to suppressing the thermal stress generated 
during its casting and cooling, the optimum annealing 
temperature ranging from 400 to 550 ºC depending on the 
glass composition.
As a rule, bioactive glasses are fairly soft, so they can be 
shaped and sized as required by using appropriate diamond 
disks or wheels under heavy refrigeration. Powdered 
bioactive glasses can be obtained by grinding or by pouring 
the melted glass into water. The latter provides a frit that is 
easy to grind but must be rapidly dried in order to avoid 
hydrolytic corrosion.
2.2. Reactivity in physiological media
As noted earlier, for bioactive glasses to bond to bone 
tissue, a biologically active layer of carbohydroxyapatite 
(CHA) must be formed on the surface of the implanted 
material; this is probably the sole common feature of all 
bioactive materials known to date (24).
The ability of bioactive glasses to bond to bone tissue is a 
result of their chemical reactivity in physiological media. The 
underlying bonding mechanism was first reported by Hench 
(10) and involves the following steps:
(1) leaching through the exchange of protons from the 
physiological medium with labile network-modifying ions 
such as Na+, K+, Ca2+, Mg2+, etc.:
Si – O – Na+ + H+ + OH− →  Si – OH+ + Na+ (solution)+ OH−
              [2]
The reaction rate and the formation of silanol groups (Si-
OH) at the bioactive glass/solution interface are diffusion-
controlled and exhibits a t -1/2dependence. The cation-
exchange process increases the concentration of hydroxyl 
ions at the bioactive glass/solution interface, thereby raising 
the pH to levels around 10.5 as shown by De Aza et al. (25) 
from interfacial pH measurements made with a microsensor 
(ISFET) on various bioactive materials.
(2) The previous pH rise facilitates dissolution of the 
Partially replacing CaO with MgO or CaF2, or Na2O 
with K2O, causes little change in bioactivity. By contrast, 
adding fluoride decreases the dissolution rate and alters 
the position of the boundary between regions A and C. 
Also, B2O3 and Al2O3 have been used to alter the production 
process of glasses or their surface dissolution rate. The 
amount of alumina added must be carefully controlled 
in order to avoid inhibiting the bioactivity of the glass 
completely. The maximum amount that can be used depends 
on the particular composition of the glass, but rarely exceeds 
1.0 or 1.5 wt%. The addition of other multivalent cations 
usually shrinks region A in Figure 2 and can even suppress 
bioactivity altogether, as found by gross and Strunz (11, 12) 
with Zr4+, Ta5+ and Ti4+ in addition to Al3+.
On the other hand, Anderson et al. (13), by applying a 
statistical method to the results of an in vivo study involving 
16 types of SiO2-CaO-Na2O-P2O5 glasses, they developed the 
following empirical relation between the response of a glass 
(RN) implanted in rabbit tibia and its composition:
RN = 88.3875 – 0.0116272 [SiO2]
2 – 0.980188 [Na2O] – 1.12306 
[CaO] – 1.20556 [P2O5] – 0.560527 [B2O3] – 2.08689 [Al2O3]         
              [1]
where the quantities in brackets represent the percentages 
by weight of the different oxides in the glass. Both the 
regression coefficient (r2 = 0.9725) and the standard deviation 
(+ 0.42 RN units) were reasonably good. The model is 
applicable over the composition ranges listed in Table II.
TABlE II. APPlICABIlITy RANgES, IN WT%, OF THE EqUATION [1].
Compound Minimum Maximum
SiO2
Na2O
CaO
P2O5
B2O3
Al2O3
38
15
10
0
0
0
65
30
24
8
3
3
The model not only measures implant biocompatibility, 
but also discriminates between acceptably (RN = 4) and 
tightly bonded implants (RN > 5). It should be noted that 
Bioglass® 45S5 exhibited a value of RN = 6.
The presence of P2O5 was initially thought to be essential 
for glasses to be bioactive. However, li et al. (14) showed 
that glasses of the SiO2-CaO-Na2O system containing no 
phosphate ions, which had been prepared via a sol-gel 
procedure, were bioactive even with as much as 85 mol% 
SiO2. In addition, Ohura et al. (15) showed that a calcium 
silicate binary glass, called CS and containing 48.3 wt% 
CaO and 51.7 wt% SiO2, it joins firmly to bone tissue. 
Subsequently, De Aza et al. (16-19) showed, for the first time, 
that a crystalline compound other than hydroxyapatite and 
containing no phosphate (viz. wollastonite, CaSiO3) not only 
exhibits a high bioactivity in both simulated body fluid (SBF) 
and parotid saliva, but also bonds strongly to bone tissue 
(20, 21).
In summary, most glasses capable of bonding to living 
tissues contain phosphates and all contain silicates; the 
latter provide a scarcely soluble matrix that offsets the excess 
solubility of phosphates glasses. Also, bioactive glasses can 
be classified into two large groups according to whether they 
are: (a) rich in alkalis (viz. those developed by Hench et al.), 
which contain more than 20 wt% alkali oxides, or (b) poor in 
-
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network and formation of additional silanol groups according 
to the reaction:
- Si – O – Si - + H – O – H   →   2 [Si – OH+]   
[3]
as well as the loss of soluble silica as Si(OH)4 that passes into 
the solution .
(3) Polymerization of the SiO2-rich layer through 
condensation of neighbouring Si-OH groups, which produces 
a layer rich in amorphous silica:
              [4]
(4) Migration of Ca2+ and PO4
3- ions to the surface of the 
silica-rich layer to form an amorphous film rich in CaO-
P2O5, followed by thickening of the film by incorporation of 
soluble Ca2+ and PO4
3- ions from the solution.
(5) Crystallization of the amorphous CaO-P2O5 film by 
incorporation of OH-, CO3
2- or F- ions from the solution, to 
form a carbohydroxyapatite or fluorocarbohydroxyapatite.
Step (4), which involves the migration of calcium and 
phosphate ions across the amorphous silica layer, in order to 
facilitate the nucleation of calcium and phosphate ions from 
the physiological medium, has been deemed unnecessary. 
Especially after Ohura et al. (15) and De Aza et al. (16-19) 
demonstrated the formation of a CHA layer on Ca-SiO2 
glasses and wollastonite (CaSiO3) respectively, both of which 
contain no phosphate ions and bond to bone tissue (20, 21. 
26 - 27).
Therefore, Karlsson et al. (28) concluded that, for glass to 
be bioactive, it must form a surface layer of amorphous silica. 
Silica gel provides a large number of sites with distances 
between –O- O-- ions favoring chelation. Consequently, the 
chelation of phosphate ions by silica gel may thus be the 
initial step, calcium ions remaining bonded to phosphate 
ions through charge compensation as follows:
later on, Anderson and Karlsson (29) modified the 
chelation hypothesis and suggested that an active site might 
hold two phosphate ions bonded to two separate silicon 
atoms, the former being bonded to a calcium ion as follows:
Based on the predominantly ionic character of the bond, 
the resulting complex cannot be considered a chelate. The 
effect inhibitor of the aluminium could be explained in this 
way, because when replacing this to the calcium it would give 
place to a more covalent bond and hence a true chelate.
One other, simpler hypothesis by De Aza et al. (25) is 
that the interfacial pH may result in precipitation of Ca2+ 
and PO4
3- ions from the solution. This is consistent with the 
fact that no amorphous silica layer was detected between 
the CHA layer and the bioactive material in the A/W glass-
ceramics developed by Kokubo et al. (30-32) or the pSW/α-
TCP Bioeutectics® obtained by De Aza et al. (33-38).
2.3. Mechanism of bonding to living tissues
The surface of an implanted bioactive glass seemingly 
undergoes the five above-described steps irrespective of 
whether some tissue is present. However, for a bioactive 
glass to bond to a tissue a series of additional interfacial 
reactions, that are more ill-defined as a result of the poor 
knowledge about the biological processes involved, are 
required. According to Hench and Andersson (39), such 
interfacial reactions occur in the following sequence:
(a) Adsorption of biological components on the CHA 
layer;
(b) Action of macrophages;
(c) Bonding of stem cells;
(d) Differentiation of stem cells;
(e) generation of the matrix; and
(f) Mineralization of the matrix.
Based on the analysis of the interface between Bioglass® 
and tissue (Fig. 3) conducted by Wilson et al. (40, 41), it 
was concluded that the bond was due to a combination of 
chemical and mechanical factors.
OH−
Fig. 3- EMP analysis of the Bioglass®45S5/bone interface (40).
Seemingly, collagen fibres provide scaffolding with the 
sites required for the micro-nucleation of apatite crystals 
(42), taking place an interdigitation of the collagen with the 
surface of the material (5). Apatite crystals grow epitaxially 
across the bone-implant interface; this means, in bone 
biology terms, that CHA crystals grow oriented along the 
collage fibres (43-46);. However, according to Davies (47), no 
unambiguous bonding mechanism has yet been proposed.
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3. MECHANICAL STRENGTH OF THE BONE-IMPLANT 
INTERFACE
The mechanical strength of the interface between a 
bioactive glass and living tissue decreases with increasing 
thickness of the interface. Such a thickness is proportional 
to the bioactivity index (IB) of the particular biomaterial 
(48). Thus, Bioglass® 45S5, which possesses a high IB value, 
forms a 200 μm thick interface with a relatively low torsional 
strength. By contrast, the glass-ceramic Cerabone A/W®, 
with a medium IB value, produces an interface 20-25 μm thick 
that possesses a high strength. The interfacial strength, Sf , 
can be calculated from the expression
Sf = c1d
-1tx = c2IB
-1tx
where d is the interface thickness, IB is the bioactivity 
index of the material, and c1, c2 and t
x are three time-
dependent variables. According to Hench (10), the optimum 
interfacial bond strength corresponds to an IB value of ca. 4. 
The interfacial strength is time-dependent and a function 
of morphological factors such as the variation of the interfacial 
area with time and the extent of mineralization of interfacial 
tissues, which increases the elastic modulus with time. 
quantifying all these variables is quite a difficult task.
In many cases, the interfacial adhesion strength is 
comparable to, or even greater than, the strength of the 
biological material or the bone itself, so fracture occurs in the 
implant or bone, but hardly ever at the interface (49).
Hench et al. (50, 51) found that, if a Bioglass® implant, 
immobilized for a critical length of time, bonds to adjacent 
tissue, the strength of the bond is identical with that of 
healthy cortical bone.
Biomechanical measurements on femoral implants in 
primates (52, 53) have revealed that the bond between a 
ceramic implant coated with Bioglass® 45S5 and bone is so 
strong that fracture under a torsional force migrates across 
the implant or surrounding bone without breaking the 
implant-bone interface.
4. BIOACTIVE GLASS-CERAMICS
A glass-ceramic material is one that has been obtained 
by using an appropriate thermal treatment of glass that 
results in the nucleation and growth of specific crystal 
phases within the residual vitreous matrix.
The high interest of bioactive glass-ceramic materials, 
in the biomedical field, has been aroused by two interesting 
advantages. One is that such materials can be obtained in 
highly complex shapes; in fact, the first step of the process 
involves producing a glass that can be obtained by using a 
variety of well-known, inexpensive techniques, including 
casting, blowing, pressing or rolling. The other advantage 
is that, by effect of the subsequent crystallization of the 
glass, glass-ceramic materials usually possess a very fine 
microstructure, containing few or no residual pores, these 
features resulting in improved mechanical properties in the 
end-product.
However, the crystallization process requires a 
well-founded knowledge of the nucleation and growth 
mechanisms of the crystal phases. Figure 4 shows a sketch 
of the rates of crystal nucleation and growth as a function of 
temperature. The rate of formation of the crystalline nuclei 
(i.e. the number of nuclei forming per unit volume and 
time) presents a maximum to a temperature that is strongly 
dependent on the particular mechanism but is usually close 
to the glass transition temperature (Tg), which corresponds 
to a viscosity of ca. 1013.3 Pa·s.
The growth rate of crystal nuclei, as a length per unit 
time, usually exhibits a maximum, around 100 ºC below 
the liquidus temperature (Tl) and, as the temperature 
diminished, it drops to very low values by effect of the 
viscosity increasing as the glass transition temperature, Tg, is 
approached. As can be seen from Fig. 4, a broad temperature 
range usually exists below Tl where no nucleation occurs 
even if crystals grow at a substantial rate.
Fig. 4- Sketch of the rate of crystal nucleation (Vn) and growth (Vg) as 
a function of temperature. Tl denotes the liquidus temperature and 
Tg the glass transition temperature. 
Fig. 5- Simplified scheme of the two-step thermal treatment used to 
obtain a glass-ceramic material.
Figure 5 depicts the typical scheme of a two-step process 
leading to the formation of a glass-ceramic material.
Once the vitreous material is at room temperature, it is 
heated at its optimum nucleation temperature. The heating 
rate used is not critical, but due care must be exercised to 
avoid large temperature gradients. A rate of 2 to 5 ºC/min 
is typically employed, the specific choice depending on the 
size of the starting product. It is convenient a high nucleation 
rate, preferably near the maximum, whose temperature 
stays constant for a certain time. Alternatively, the glass 
can be directly cooled to the nucleation temperature once 
shaped (dotted line in Figure 4).
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of the Ca3(PO4)2-CaSiO3-MgCa(SiO3)2 system, starting from a 
monolithic glass or even powdered glass, the glass-ceramic 
A/W was obtained by adding a small amount of CaF2 to the 
original composition. glass ground to an average particle 
size of 5 μm was isostatically pressed at 200 MPa in the 
desired shapes and thoroughly densified at ca. 830 ºC, 
which resulted in the precipitation of oxyfluorapatite and β-
wollastonite at 870 and 900 ºC, respectively. The end-product 
was thus a glass-ceramic with a very fine microstructure free 
of cracks and pores.
The next step is critical. The temperature must be raised 
slowly usually at no more than 5 ºC/min in order to avoid any 
stress due to volume change during crystallization, which 
could result in cracking or even fracture of the material. Slow 
heating facilitates suppression of such stress via viscous flow 
in the residual glass, the material becoming increasingly 
rigid as the crystal fraction increases. Once the “growth” 
temperature is reached, it is held for the time required to 
achieve the desired degree of crystallinity. Finally, the glass-
ceramic product is cooled to room temperature.
Depending on the particular glass composition, 
crystallization can start at the surface and occur unevenly 
in the material, leading to products of low strength. Volume 
nucleation can be ensured and an appropriate microstructure 
obtained by using additives: nucleating agents. The additive 
usually consists of metal particles (Cu, Ag, Au, Pt) or a 
metal oxide (SnO2, Ce2O3, TiO2), which act favoring the 
heterogeneous nucleation of the crystal phases.
In the field of the glass-ceramics for biomedical 
applications, P2O5, which is an ingredient of all of them, has 
the same nucleation properties as TiO2.
4.1. Bioactive glass-ceramic compositions
Most biomedical glass-ceramics are based on compositions 
similar to those of Hench’s bioactive glasses (Bioglass®)(54), 
however, all of them have very low contents in alkali oxides. 
Table III summarizes the properties of bioactive glass-
ceramics used in the clinical field as compared to those of 
Bioglass® 45S5.
Ceravital®
The earliest glass-ceramic material of clinical use was 
developed by Brömer and Pfeil in 1973 (55, 56) and named 
Ceravital®. This designation, however, includes a wide range 
of glass-ceramic compositions. Originally, Ceravital® was 
believed to possess extraordinary properties as a replacement 
material even for bone in loaded zones and teeth. However, 
as can be seen from Table III, their mechanical properties, 
even for the optimum compositions, they are below the 160 
MPa of the human cortical bone and are similar to those of 
sintered dense hydroxyapatite (115 MPa).
Also, long-term in vivo tests questioned the stability of 
these materials. However, subsequently gross et al. (57, 58) 
developed improved compositions, the solubility of which 
was reduced by using various metals as nucleating agents.
The bioactivity of Ceravital® is roughly one-half that 
of Bioglass® 45S5 (5.6 versus 12.5). At present, Ceravital® 
implants are exclusively used to replace the ossicular chain in 
the middle ear, where loads are minimal and the mechanical 
properties of this material are thus more than adequate.
Cerabone® A/W
One of the glass-ceramics of more clinical success, be 
probably the denominated A/W, which is constituted by 
two crystalline phases: oxyfluorapatito Ca10(PO4)6(O,F2) and 
wollastonita (β- CaSiO3) and a residual vitreous phase. This 
was originally developed by Kokubo et al. (30-32, 59, 60) and 
is commercially available under the trade name Cerabone® 
A/W. Its composition is shown in the Table III.
After some failed attempts of producing a glass-ceramic 
TABlE III. COMPOSITION AND SElECTED PROPERTIES OF glASS-CERAMICS 
WITH ClINICAl APPlICATIONS AS COMPARED TO THOSE OF BIOglASS 45S5
Compound
(wt%)
Bioglass 
45S5.
Ceravital
Cerabone 
A/W
Ilmaplant Bioverit
Na2O
K2O
MgO
CaO
Al2O3
SiO2
P2O5
CaF2
24.5
0
0
24.5
0
45.0
  6.0
0
5-10
0.5-3.0
2.5-5
30-35
0
40-50
10-50
0
0
0
4.6
44.7
0
34.0
 6.2
0.5
4.6
0.2
2.8
31.9
0
44.3
11.2
5.0
3-8
0
2-21
10-34
8-15
19-54
2-10
3-23
Phases glass
Apatite +
glass
Apatite +
β-wollast.
+ glass
Apatite +
β-wollast.
+ glass
Apatite +
Flogopite 
+ glass
Flexural 
Strength σf 
(MPa)
Compressive
Strength 
(Mpa)
young’s 
Modulus 
(gPa)
42
n.d
35
100 – 150
500
n.d
220
1060
117
170
n.d
n.d
-
100 – 160
500
70 - 88
The special microstructure of this glass-ceramic endows it 
with the best mechanical properties among all the materials 
shown on Table III; thus, its σf (220 MPa) is nearly twice 
that of dense hydroxyapatite (115 MPa) and exceeds that 
of human cortical bone (160 MPa). In addition, its tenacity 
is ca. 2.0 MPaAm–1/2 and its Vickers hardness about 680 HV 
(61,62).
Equally that in the bioactive glasses, an apatite layer is 
formed on the surface of the glass-ceramic A/W in simulated 
body fluid and it is also attributed to this layer the capacity 
of joint to bony tissue. Due to the chemical and structural 
characteristics of this CHA, similar to the bony tissue, it is of 
expecting that, in the interface with the bone, proliferate the 
osteoblasts preferably to the fibroblasts.
However, unlike bioactive glasses, no amorphous silica 
layer between the carbohydroxyapatite (CHA) and the 
A/W glass-ceramics has been observed not even by high-
resolution electron microscopy. In any case, Kokubo and 
coworkers believe that silanol groups formed at the glass-
ceramic surface are those responsible for the formation of 
the CHA layer as they provide the favourable sites required 
for its nucleation and growth. Their hypothesis relies on the 
following mechanism for the formation of the CHA layer on 
A/W glass-ceramics: dissolution of calcium ions from the 
n.d = not determined
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glass-ceramic surface increases the ionic activity product of 
apatite in the simulated body fluid, while hydrated silica at 
the glass-ceramic surface provides favourable sites for CHA 
nucleation (see Fig. 6).
Ilmaplant-L1®
Berger et al. (63) developed this implant, which consists 
of apatite/wollastonite glass-ceramic. As can be seen from 
Table III, it differs from A/W glass-ceramics in its alkali 
contents; increased proportions of CaF2, SiO2 and P2O5; and 
decreased content in CaO. Because of its low mechanical 
bending strength (see Table III), its use is restricted to 
maxillofacial implants.
Bioverit®
In 1983, Holand et al. (64), of the University of Jena, 
developed a new series of bioactive glass-ceramics, which 
they called Bioverit® I (Table III). Bioverit® glass-ceramics can 
be readily machined with standard tools and even retouched 
in the operating theatre. These materials are obtained from a 
silicate-phosphate glass of complex composition in the SiO2-
Al2O3-MgO-Na2O-K2O-F-CaO-P2O5 system. The procedure 
involves generating phase separation in the glass, through 
controlled nucleation and subsequent growth of the crystal 
phases, by thermal treatment at 610 y 1050 ºC. The resulting 
product consists of residual glass plus a mixture of apatite 
crystals (1-2 μm in size) and a fluoroflogopite-like mica 
(Na/KMg3[AlSi3O10F2]) which facilitates machining of the 
material.
Subsequently, the same authors developed another 
family of also readily machined glass-ceramics, which they 
called Bioverit® II. As can be seen from Table IV, the new 
materials contained very little P2O5 relative to Bioverit
® I. 
like its predecessor, Bioverit® II contains fluoroflogopite-like 
mica, (whose crystals present a curved morphology that are 
not encountered in nature), in addition to other crystalline 
compounds, specially prominent among of cordierite 
(Mg2[Si5Al4O4]).
Finally, Vogel and Hölland (65, 66) developed a further 
family of glass-ceramics named Bioverit® III (see Table IV) 
from a phosphate glass containing no silica. To this end, 
they used a inverted phosphate glass in the P2O5-Al2O3-
CaO-Na2O system, consisting of mono- and diphosphate 
Fig. 6- Mechanism for the formation of the apatite layer on A/W 
glass-ceramic according to Kokubo et al.(32).
As a result, CHA nuclei rapidly form on the glass-ceramic 
surface. Once the first few nuclei have formed, they grow 
consuming calcium and phosphate ions from the simulated 
body fluid spontaneously. Although no amorphous silica 
layer has been found on the surface of A/W glass-ceramics, 
the fact that a substantial amount of silicate ions are 
dissolved in the SFA suggests that a large number of silanol 
groups are formed at the A/W glass-ceramic surface (30).
like Hench et al., Kokubo et al. believe that silanol groups 
constitute favourable sites for CHA to nucleate in both glass-
ceramics and bioactive glasses. However, these authors do 
not consider the effect of the interfacial pH on the formation 
of the CHA layer, as has been suggested by De Aza et al. (25). 
The interfacial pH is a result of the interchange of protons 
from the simulated body fluid with labile ions from the 
vitreous network. 
Although its bioactivity index, IB = 3.2, is roughly one-
fourth that of Bioglass® 45S5 (IB = 12.5), it is slightly higher 
than that of dense sintered hydroxyapatite (IB = 3.0). Upon 
implantation in a bone defect, A/W glass-ceramic forms 
a Ca- and P-rich layer through which it bonds to bone. 
Bonding is so strong that tensile fracture never occurs at 
the A/W-bone interface, but rather in the bone. The Ca- and 
P-rich layer has been identified by X-ray microdiffraction to 
consist of apatite (Fig. 7).
The good biocompatibility, bioactivity and mechanical 
properties of this glass-ceramic which facilitate its machining 
with diamonds discs and drills have fostered its use in 
reconstructing iliac crests, vertebrae and intervertebral discs 
and, in granules form, in filling in bone defects, since the 
1980s.
Fig. 7- X-ray microdiffraction pattern for the A/W-bone interface 
(32).
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structural units and doped it with Fe2O3 or ZrO2. The end 
product consisted of residual glass in addition to apatite, 
berlinite (AlPO4) and complex structures of phosphates of 
the varulite-like type (Na-Ca-Fe phosphate).
alloys (72-77). This last alloy is especially attractive on 
account of its high strength, low elasticity modulus and good 
biocompatibility. The methods used to prepare the coatings 
range from immersion in the molten glass or in a solution, 
suspension or gel (dip coating); electrophoresis from a 
solution or suspension (the metal to be coated acting as an 
electrode), biomimetic coating growth or flame or plasma 
spraying. The last choice is the most widely used at present 
to deposit a bioactive glass onto a metal substrate.
One other application of bioactive glasses is in the 
production of composites, being reinforced the bioactive glass 
with a second phase. The materials thus obtained include 
“biofibre glass” and alumina, organic polymers or metal 
fibres. The former has fallen short of the original expectations 
as it seemingly releases large amounts of alumina powder 
that are detrimental to tissues. The materials reinforced with 
metal fibres are those with the strongest potential. In fact, 
metal fibres strengthen bioactive glasses and improve their 
deformability. The most widely used procedure for producing 
these materials is hot pressing (78, 79).
Ducheyne and Hench (80) reported a composite material 
consisting of Bioglass® 45S5 and metal fibres of AISI 
316l stainless steel. The material, which was prepared 
by immersing the metal fibres in molten glass, exhibited 
improved mechanical strength and ductility, in addition to a 
young modulus comparable to that of human cortical bond.
Other glass-based composite materials include Ceravital® 
reinforced with titanium particles (81) and A/W glass-
ceramic reinforced with partially stabilized zirconia (82) or 
polyethylene (83).
The essential requirements for these composite materials 
to be useful as dental implants or in orthopaedic applications 
are a low elasticity modulus, good deformability, good tensile 
strength and good impact resistance and ready machining.
6. CLINICAL USES OF BIOACTIVE GLASSES AND 
GLASS-CERAMICS
Some uses of bioactive glasses and glass-ceramics have 
been described above in dealing with various aspects of 
these materials. Interested readers are referred to the 
comprehensive reviews by gross et al. (57), Hench and 
Wilson (5), and yamamuro (84, 85), for a wider description.
Bioglass® is typically used in implants intended to 
preserve the alveolar chain or partly or completely replace 
the ossicular chain of the middle ear in patients with chronic 
otitis. Merwin et al. (86) have demonstrated the long-term 
stability of these implants resulting from their bonding to 
the tympanic membrane.
After eight years of clinical use of Ceravital®, Reck et al. 
(87) concluded that this material provides the most effective 
prostheses for complete reconstruction of the ossicular 
chain.
The use of A/W glass-ceramic prostheses for iliac 
crest reconstruction has so far provided clinically and 
radiologically acceptable results (84).
Animal testing has shown that Bioglass® coatings are 
useful to obtain durable hip prostheses by effect of combining 
high bioactivity and mechanical strength, which avoids of 
using bony cement to attach implants to bone.
Table V summarizes the most common uses of the 
different types of bioactive glasses and glass-ceramics in 
various presentation forms.
TABlE IV. COMPOSITION AND SElECTED PROPERTIES OF THE BIOVERIT TyPES 
II AND III
Compound
Bioverit II
 (wt%)
Bioverit III 
 (wt%)
SiO2
Al2O3
MgO
Na2O/K2O
F
Cl
CaO
P2O5
(MeO/Me2O5/MeO2)*
43 – 50
26 – 30
11 – 15
7 – 10.5
3.3 – 4.8
0.01 – 0.6
0.1 – 3
0.1 – 5
---
---
6 – 18
---
11 – 18
---
---
13 – 19
45 – 55
1.5 - 10
Density (gr/cm3)
Coefficient of Expansion (K-1)
Flexural strength (MPa)
Toughness (KIC) (MPa·m
½)
young’s Modulus (gPa)
Compressive strength (MPa)
Vickers hardness (HV 10)
Hydrolytic Class (DIN 12111)
Roughness (after polishing) (μm)
2,5
7.5 – 12 · 10-6
90 – 140
1.2 – 1.8
70
450
up to 8000
1 - 2
0.1
2.7 – 2.9
14 – 18 ·10-6
60 – 90
0.6
45
---
---
2 – 3
---
* (MnO, CoO, NiO, FeO, Fe2O3, Cr2O3, ZrO2)
The contents in crystalline phases and vitreous matrix 
in Bioverit® glass-ceramics can be modified with a view 
to modulating their physical properties and bioactivity by 
changing the ingredient contents within the composition 
ranges shown in Tables III and IV. Thus, translucence in these 
materials is a function of the proportion of crystal phases, 
whereas machinability depends on their mica content (e.g. 
Bioverit® II is easier to machine than is Bioverit® I). In 
addition, the material colour can be modified by addition 
of small amounts of oxides such as NiO, Cr2O3, MnO2, FeO, 
Fe2O3, etc.
By the mid-1990s, more than one thousand bone 
replacement implants had been successfully fitted in 
various biomedical fields including orthopaedic surgery 
(e.g. acetabular reconstruction, vertebral replacement, tibial 
head osteoplastic, joint plastic surgery) and head and neck 
surgery (middle ear implants, orbital base repair, cranial 
base reconstruction, rhinoplasty, etc.).
5. BIOACTIVE GLASS COATINGS AND COMPOSITES
As noted earlier, the greatest constraint on a wider use 
of bioactive glasses and glass-ceramics is derived from 
their relatively poor mechanical properties, especially in 
zones under mechanical loads. This shortcoming has been 
circumvented by using various methods to increase the 
strength of these glass materials and facilitate their use as 
implants.
One solution to the problem is using bioactive glasses 
as a coating for materials with a high mechanical strength. 
This method has been used with a number of substrates, 
including dense alumina (67, 68), various types of stainless 
steel (69, 70), cobalt-chromium alloys (71) and titanium 
P.N. DE AzA,* A.H. DE AzA, P. PENA AND S. DE AzA
52 Bol. Soc. esp. Ceram. V., 46 [2] 45-55 (2007)
ACKNOWLEDGEMENTS
The authors wish to acknowledge funding from Spain’s 
CICyT within the framework of Projects MAT2003-08331-
C02-01-02 and MAT2006-12749-C02-01-02 and generalitat 
Valenciana (gVA) ACOMP06/044.
REFERENCES
1. l.l. Hench. “Bioactive ceramics”, in Bioceramics: Materials Characteristics 
Versus In Vivo Behaviour, Eds. P. Ducheyne and J.E., lemons, Annals of 
New york Academy of Science, New york, Vol 523, 54, (1988).
2. l.l. Hench. “Bioceramics”. J. Am. Ceram. Soc. 81, 1705-1728 (1998)
3. P.N. De Aza, A.H. De Aza and S. De Aza. “Crystalline Bioceramic 
Materials”, Bol. Soc. Esp. Ceram. V., 44 [3] 135-145 (2005).
4. l.l. Hench, R.J. Splinter, W.C. Allen and T.K. greenlee. “Bonding 
mechanisms at the interface of ceramic prosthetic materials”, J. Biomed. 
Mater. Res. Symp. 2 (1) 117-41. (1971). 
5. l.l., Hench and J. Wilson. “Surface-active biomaterials”, Science. 226, 630 
(1984).
6. l.l. Hench and M.M. Walker. U.S. Patent 4, 171, 544 (1978).
7. g.M. Morey and N.l. Bowen. “High SiO2 of the system SiO2-CaO-Na2O” in 
Phase Diagram for Ceramists, Edit. The Am. Ceram. Soc., Fig. 481, (1964).
8. C. Beckham, T. greenlee and A. Crebo. J. Calcified Tissue Res. 8, 165 
(1971).
9. T;greenlee, C.;Beckham, A. Crebo and J. Malmborg, J. Biomed. Mater. Res. 
6, 244. (1972).
10. l.l.Hench. “Bioceramic: From Concept to Clinic”, J. Am. Ceram. Soc., 
74[7] 1487-1570 (1991).
11. U.gross and V. Strunz. “The Anchoring of glass Ceramics of Different 
Solubility in the femur of the rat”, J. Biomed. Mater. Res., 14, 607 (1980).
12. U. gross y V. Strunz. “Clinical Application of Biomaterials”. Ed. A.J.C. lee, 
T. Albrektsson, P. Branemark, John Wiley & Son, New york, 237 (1982).
13. Ö.H. Anderson, K.H. Karlsson and K. Kanganiemi. “Calcium phosphate 
formation at the surface of bioactive in vivo”, J. Non-Cryst. Solids, 119, 
290-296 (1990).
14. R. li, A.E. Clark and l.l. Hench. “An investigation on bioactive glass 
powders by sol-gel processing”, J. Appl. Biomaterials, 2, 231-239 (1991).
15. K., Ohura, T., Nakamura, T., yamamuro, T. Kokubo, T., Ebisawa, y., Kotoura, 
M., Oka. “Bioactivity of CaO SiO2 glasses added with various ions”, J. 
Mater. Sci. Mater. Med., 3, 95-100 (1992).
16. P.N. De Aza, F. guitian and S. De Aza. “Bioactivity of wollastonite 
ceramics: in vitro evaluation”. Scripta Metall. Mater., 31, 1001-1005 (1994).
17. P.N. De Aza, F. guitian and S. De Aza. “Polycrystalline wollastonite 
ceramics. Biomaterials free of P2O5”, in Advances in Science and 
Technology 12; Materials in Clinical Applications. P. Vincenzini, editor. 
Publ. Techna Srl., pp. 19-27 (1995).
18. P.N. De Aza Z.B luklinska, M.R., Anseau, F. guitian and S. De Aza 
“Morphological studies of Pseudowollastonite for biomedical application”, 
Journal of Microscopy; 182, 24-31 (1996).
19. P.N. De Aza, ZB, luklinska M,. Anseau F. guitián and S. De Aza. 
“Bioactivity of pseudowollastonite in human saliva”, J Dent;27, 107-113 
(1999).
20. P.N. De Aza, Z.B. lublinska, A. Martínez, M.R. Anseau, F. guitián and 
S.De Aza. “Morphological and structural study of pseudowollastonite 
implants in bone”. Journal of Microscopy 197, Pt. 1, 60-67 (2000)
21. P.N. De Aza, Z.B. luklinska, M.R. Anseau, F. guitián and S. De Aza. 
“Transmission electron microscopy of the interface between bone and 
pseudowollastonite implant”, J Microscopy-Oxford, 201, Pt. 1, 33-43 
(2001).
22. l.l. Hench. “Biomaterials: a forecast for the future”. Biomaterials 19, 
1419–1423 (1998).
23. l.l. Hench. “Sol-gel materials for bioceramic application”. Current 
Opinion in Solid State and Materials Science, 2(5) 604-610 (1997).
24. O.P. Filho, g.P. la Torre & l.l. Hench. “Effect of crystallization on apatite-
layer formation on bioactive glass 45S5”. J. Biomed. Mater. Res., 30, 509-
514 (1996).
25. P.N. De Aza, F. guitian,, A. Merlos, E. lora-Tamayo and S. De Aza. 
“Bioceramics-Simulated body fluid interfaces: pH and its influence on 
Hydroxyapatite formation”, J Mater Sci. Mater Med 7(7) 399-402 (1996).
PRESENTATION MATERIAl ClINICAl APlICATION 
Dense materials 
Bioglasses
Maxillofacial reconstruction
Middle ear reconstruction 
Junction of spinal vertebrae 
Dental implants
Percutaneous access devices
glass-ceramics
Dental implants
Maxillofacial reconstruction
Vertebral prosthesis devices
Iliac crest prostheses
Porous materials
 
Bioglasses
(porous surfaces) It doesn’t have any application until today
Coating
Bioglasses on Al2O3
(high density)
Maxillofacial reconstruction
Middle ear reconstruction 
Junction of spinal vertebrae 
Bioglasses on stainless steel
Hip articulation prostheses
Attachment of artificial members to the bone 
Isolation of neuronal electrodes
Bioglasses on Ti or
Ti-alloys Bone  prostheses
Composites
Al2O3 + Bioglasses It doesn’t have any application until today
Polymers + Bioglasses
Joints of soft tissues/bone. Cements.
TABlE V. BIOACTIVE glASSES AND glASS-CERAMICS AND THEIR ClINICAl APPlICATIONS
BIOACTIVE gLASSES AND gLASS-CERAMICS
53Bol. Soc. esp. Ceram. V., 46 [2] 45-55 (2007)
26. M.M. Walter. “An investigation into the bonding Mechanism of Bioglass”. 
Master Thesis, University of Florida, gainsville (1977).
27. Ö.H. Andersson, g. liu, K.H. Karlsson, J. Miettinen and Juhanoja. “In vivo 
behaviour of glasses in the SiO2-Na2O-CaO-P2O5-Al2O3-B2O3”, J. Mat. Sci. 
Mater. Med. 1, 219-227 (1990).
28. K.H. Karlsson, K. Fröberg and T. Ringbom. “Structural approach to bone 
adhering of bioactive glasses”, J. Non.Cryst. Solids, 112, 69-72, 1989. 
29. Andersson, Ö.H.; Karlsson, K.H. “On the bioactivity of silicate glass”, J. 
Non-Cryst. Solids, 129 145-51 (1991).
30. T. Kokubo, S., Ito, S. Sakkay y. and yamamuro. “Formation of a High 
Strengh Bioactive glass-Ceramic in the System MgO-CaO-SiO2-P2O5”, 
J. Mater. Sci., 21 536-540 (1986).
31. T. Kokubo, T. Hayashi, S. Sakka, T. Kitsugi and T. yamamuro. “Bonding 
between Bioactive glass, glass-Ceramic or Ceramics in Simulated Body 
Fluid”, yogyo-Kyokai-hi., 95 (8) 785-791 (1987).
32. T. Kokubo. “A-W glass-Ceramic: Processing and Properties” in 
Introduction to Bioceramcs, Eds. by l.l.Hench and J. Wilson, Singapore, 
75-88 (1993).
33. P.N. De Aza, F. guitián and S. De Aza. “Bioeutectic: a new ceramic material 
for human bone replacement”. Bioceramics, 18, 1285-1291 (1997).
34. P.N. De Aza, F. guitián and S. De Aza. “Eutectic Structures that Mimic 
Porous Bone”. In Ceramic Microstructure control at the atomic level. Eds., 
A.P.Tomsia, and A. glaeser, Plenum Publ. Corp. N.y. 761-769 (1998).
35. P. N.De Aza, Z. B. luklinska, M.R. Anseau, F. guitian and S. De Aza. 
“Electron microscopy of interfaces in a wollastonite–tricalcium phosphate 
bioeutectic”, J. of Microscopy,189, 145-153 (1998).
36. P.N. De Aza, F. guitian and S. De Aza. “A New Bioactive Material which 
Transform in situ into Hydroxyapatite”, Acta Met. et Materialia, 76(7), 
2541-2549. (1998).
37. P.N. De Aza, F. guitian S. De Aza. “Bioeutectics: A New Bioceramic 
Materials”. In Advances in Science and Technology 28 Materials in Clinical 
Application, Editor P. Vincenzini, Publ. Techna Srl., pp. 25-32 (1999).
38. P.N. De Aza, Z.B. luklinska, M. Anseau, F. guitián and S. De Aza. 
“Reactivity of a wollastonite-tricalcium phosphate bioeutectic”, 
Biomaterials; 21(17) 1735-1741. (2000).
39. l.l. Hench and Ö. Andersson. “Bioactive glasses”. In An introduction 
to Bioceramics, Edit., by l.l. Hench and J. Wilsob. Publ. World Scientific, 
Chapt. 3, pp. 41-62 (1993).
40. J.Wilson, F.J. Schoen, g.H. Pigott and l.l. Hench. “Toxicology and 
biocompatibility of Bioglasses”, J. Biomed. Mater. Res. 15 (6) 805 (1981).
41. J. Wilson, S. low, A. Fetner and l.l. Hench. “Bioactive materials for 
periodontal applications”, in Biomaterials in Clinical Applications, 223, 
Ed. A. Pizzoferrato, P.g. Marchetti, A. Ravaglioli and A.J.C.lee, Elsevier, 
Amsterdam. (1987).
42. D.B. Spilman, J. Wilson and l.l. Hench. “In vivo and in vitro investigations 
into Bioglasses which contain fluoride”, in Biomaterials 84, Vol 7, Trans. 
2nd World Congr. Biomaterials. Ed. Anderson, J. Society for Biomaterials, 
pp. 287 (1984).
43. M.J. glimcher. “Specificity of the molecular structure of organic matrices 
in mineralization”, in Calcification in Biological Systems, Ed. Sognnaes, 
R.F. American Association for the Advancement of Science, Washington, 
D.C., pp. 421 (1960).
44. M.l Watson and J.K Avery. “The development of hamster lower incisor as 
observed by electron microscopy”, Am. J. Anat. 95 109. (1954).
45. W.F. Neuman and M.W. Neuman. “The nature of the mineral phase 
bone”, Chem. Rev. 53 1. (1953).
46. P.q. Ducheyne. “ Bioactive ceramics the effect os surface reactivity on 
bone formation and bone cell function”. Biomaterial 20 (23-24) 2287-2303 
(1999).
47. J.E. Davies. “The use of cell and tissue culture to investigate bone cell 
reactions to bioactive materials”, in Handbook of Bioactive Ceramics, Vol.
II, Calcium Phosphate and Hydroxylapatite Ceramics, Ed. T. yamamuro, 
l.l. Hench, J. Wilson, CRC Press, Boca Raton, Fl., pp. 195-225 (1990).
48. l.l. Hench. “Bioactive glasses and glass.Ceramics: A Perspective”, in 
Handbook of Bioactive Ceramics, Eds. T. yamamuro, l.l. Hench, J. Wilson, 
CRC Press, Boca Raton, Fl., Vol. I, pp.7-39 (1990).
49. l.l. Hench and A.E. Clark. “Adhesion to bone”, in Biocompatibility of 
Orthopedic Implants, Vol 2, Cap 6, Ed. Williams, D.F., CRC Press, Boca 
Raton, Fl. (1982).
50. l.l. Hench, T.K. greenlee, W.C. Allen, g. Piotrowski. “An investigation 
on bonding mechanism at the interface of a prosthetic material”, 
Rep. No. 9, Contract. No. DADA 17-70-C-001, U.S. Army Research 
and Development Command, Clearinghouse for Federal Scientific and 
Technical Information, Washington, D.C. (1978).
51. I.D. Thompson & l.l. Hench. “Mechanical properties of bioactive glasses, 
glass-ceramics and composites”. Proc. Inst. Mech. Eng., 212(2) 127-136 
(1998).
52. l.l. Hench and D.E. Clark. “Physical chemistry of glass surfaces”, J. Non-
Cryst. Solids 28 [1] 83. (1978).
53. g. Piotrowski, l.l. Hench, W.C. Allen and g.J. Miller. “Mechanical studies 
of the bone-Bioglass interfacial bond”, J. Biomed. Mater. Res. 9 [6] 47. 
(1975).
54. O. Peitl, E. Dutra Zanotto anf l.l. Hench. “ Highly bioactive P2O5-Na2O-
CaO-SiO2 glass-ceramics”. Journal of Non-Crystalline Solids, 292(1-3) 
115-126 (2001).
55. H. Brömer, E Pfeil and M. Kos. “german Patent”. No 2,326,100. (1973).
56. H. Brömer, K. Deutscher, B. Blenke, E. Pfeil and V. Strunz. “Properties of 
the bioactive implant material Ceravital”, Sci. Ceram. 9, 219-25. (1977).
57. U. gross, R. Kinne, H.J Schmitz and V. Strunz. “The response of bone 
to surface active glass/glass-ceramics”, CRC. Crit. Rev. Biocompat. 4 (2). 
(1988).
58. U. M. gross, C Müller-Mai and C Voigt. “Ceravital bioactive glass-
Ceramic”. In An introduction to bioceramics, Edit. l.l Hench & J, Wilson, 
Singapore: World Scientific Publishing Co., pp. 105-124 (1993)
59. T. Kokubo, S. Ito, T. Hayashi, S. Sakka, T. Kitsugi, T. yamamuro, M. Takagi, 
and T. Shibuya. “Structure and Properties of a load-Bearable Bioactive 
glass-Ceramic”, XIV Inter. Congr. on glass, II, 408-415 (1986 b).
60. T. Kokubo. “Novel Ceramics for Biomedical Applications”, Third Euro-
Ceramics. Edit. P. Durán and J.F. Fernandez, Vol. 3, 1-16 (1993).
61. T. Kokubo, S. Ito, M. Shigematsu, S. Sakka, T. yamamuro. “Mechanical 
Properties of a New Type of Apatite Containing glass-Ceramic for 
Prosthetic Application”, J. Mater. Sci., 20, 2001-2004 (1985).
62. T. Kokubo, S. Ito, M. Shigematsu, S. Sakka and T. yamamuro. “Fatigue 
and life-Time of Bioactive glass-Ceramic A/W Containing Apatite and 
Wollastonite”, J. Mater. Sci., 22 4067-4070 (1987).
63. g. Berger, R. Sauer, g. Steinborn, F. Wihsmann, V. Thieme, St. Kholer and 
H. Dressel. “Clinical application of surface reactive apatite/wollastonite 
containig glass-ceramics”, Proceedings of XV International Congress on 
glass, Ed. Mazurin, O.V., Nauka, leningrado, pp. 120-26, (1989).-
64. W. Höland,. J. Naumann, W. Vogel, J. gummel, Z. Wiss and F. Schieler. 
Univ. Jena Math. Naturwiss, Reihe 32, 571-80 (1983).
65. W. Vogel and W. Höland. “The development of bioglass ceramics for 
medical applications”, Angew. Chem. Int. Ed. Engl. 26, 527-44 (1987).
66. W. Vogel and W. Höland. “Development, properties and application of 
bioglass-ceramics in medicine”, Adv. Fusion glass, 33.1-33.16 (1988).
67. l.l. Hench and D.C. greenspan. “Bioglass coated Al2O3 ceramics”, U.S. 
Patent, 4, 103, 002. (1978).
68. D.C. greenspan and l.l. Hench. “Chemical and mechanical behavior of 
Bioglass coated alumina”, J. Biomed. Mater. Res. 10 (4), 503 (1976).
69. l.l. Hench, C.g. Pantano, P.J. Buscemi and D.C. greenspan. “Analysis 
of Bioglass fixation of hip prosthesis”, J. Biomed. Mater. Res. 11 (2) 267 
(1977).
70. g. Piotrowski, l.l. Hench, W.C. Allen and g.J. Miller. “Mechanical studies 
of the bone-Bioglass interfacial bond”, J. Biomed. Mater. Res. 9 (6) 47 
(1975).
71. W.R. lacefield and l.l. Hench. “The bonding of Bioglass to a cobalt-
chromium medical and dental alloy”, Ph. D. Thesis, Florida University, 
gainesville (1981).
72. J.K. West, A.E. Clark, M.B. Hall and g.E. Turner. “In vivo bone bonding 
study of Bioglass coated titanium alloy”, in Handbook of Bioactive 
Ceramics, Vol I, Bioactive glasses and glass Ceramics, Ed. T. yamamuro,; 
l.l. Hench, J. Wilson, CRC Press, Boca Raton, Fl., pp. 161-6 (1990).
73. J.M. gómez-Vega, et. al. “Bioactive glass coating with hydroxyapatite an 
Bioglass particles on Ti-based implants”. Processing Biomaterials 21(2) 
105-111 (2000)
74. C. garcía, S. Caré and A. Durán. “ Bioactive Coatings deposites on 
titanium alloys”. Journal of Non-Crystalline Solids, 352(32-35) 3488-3495 
(2006).
75. C. garcía, S. Caré and A. Durán. “Boactive coatings prepared by sol-gel 
on stainless 316l”. Journal of Non-Crystalline Solids, 348(15) 218-224 
(2004).
76. S.J. li, M. Niinomi, T. Akahori, T. Kasuga, R. yang and y.l. Hao. “Fatigue 
characteristics of bioactive glass-ceramic-coated Ti-29Nb-13Ta-4.6Zr for 
biomedical application”. Biomaterials, 25(17) 3369-3378 (2004).
77. E. Verné, C. Fernández Vallés, C. Vitale Brovarone, S. Spriano and C. 
Moisescu. “ Double-layer glass-ceramic coatings on Ti6Al4V for dental 
implants”. Journal of the European Ceramic Society, 24(9) 2699-2705 
(2004).
78. R. Rogier, F. Pernot. “Elastic and mechanical properties of glass-ceramic 
and metal composites for orthopedic applications”. in Handbook of 
Bioactive Ceramics, Vol I, Bioactive glasses and glass Ceramics, Ed. T. 
yamamuro, l.l. Hench and J. Wilson, CRC Press, Boca Raton, Fl., pp. 
183-91 (1990)
79. O. Sakamoto and S. Ito. “Mechanical properties of bioactive glass-ceramic 
composite by SiC whiskers”, in Handbook of Bioactive Ceramics, Vol I, 
Bioactive glasses and glass Ceramics, , Eds. T. yamamuro, l.l. Hench and 
J. Wilson, CRC Press, Boca Raton, Fl., pp. 155-60 (1990).
80. P. Ducheyne and l.l. Hench. “The processing of static mechanical 
properties of metal fibre-reinforced Bioglass”, J. Mater. Sci. 17, 595-606 
(1982).
81. Ch. Müller-Mai, H.J. Schmitz, V. Strunz, g. Fuhrmann, Th. Fritz and U.M 
gross. “Tissues at the surface of the new composite material titanium/
glass-ceramic for replacement of bone and teeth”, J. Biomed. Mater. Res. 
23, 1149-61. (1989).
P.N. DE AzA,* A.H. DE AzA, P. PENA AND S. DE AzA
54 Bol. Soc. esp. Ceram. V., 46 [2] 45-55 (2007)
82. T. Kasuga, K. Nakajima, T. Uno and M. yoshida. “Bioactive glass-ceramic 
composite toughened by tetragonal zircona”, in Handbook of Bioactive 
Ceramics, Vol. I, Bioceramic glasses and glass Ceramics, Eds.  T. yamamuro, 
l.l. Hench and J. Wilson, CRC Press, Boca Raton, Fl., 137-42, (1990).
83. J.A. Juhasz, S.M. Best, R. Brooks, M. Kawashita, N. Miyata, T. Kokubo, 
T. Nakamura and W. Bonfield. “Mchanical properties of glaa-ceramic 
A-W-polyethylene composites: effect of filler content and particle size”. 
Biomaterials, 25(6) 949-955 (2004).
84. T. yamamuro. “A/W glass-Ceramic: Clinical Aplication”, in An 
Introduction to Bioceramics, Eds. l.l. Hench and J. Wilson, Publ. World 
Scientific Publ. Co. Pte. ltd, pp. 89-104 (1993).
85. T. yamamuro, J. Shikata, y. Kakutani, S. yosii, T. Kitsugi and K. Ono. “Novel 
Methods for Clinical Applications of Bioactive Ceramics” in Bioceramics: 
Materials Characteristics Versus In Vivo Behavior, Eds. P. Ducheyne and 
J. lemons, Annals of New york Academy of Sciences, New york, 523, 107-
114 (1988).
86. g.E. Merwin, J.S. Atkins, J. Wilson and l.l. Hench. “Comparison of 
ossicular replacement materials in a mouse ear model”, Otolaryngology, 
Head, Neck Surg. 90 461 (1982).
87. R. Reck, S. Storkel and A. Meyer. “Bioactive glass-ceramic in middle 
ear surgery: an 8-year review”, in Bioceramics: Materials characteristics 
versus in vivo behaviour, Ed. Ducheyne, P.; lemons, J., Annals of New york 
Academy of Sciences, New york, Vol. 523, 100 (1988).
Recibido:    20.11.06
Aceptado:   23.01.07
BIOACTIVE gLASSES AND gLASS-CERAMICS
55Bol. Soc. esp. Ceram. V., 46 [2] 45-55 (2007)
